Cingulate Inc (CING)

$4.76 -0.22 (-4.42%)
Market Cap 16.00M
Revenue (ttm) 0.00
Net Income (ttm) -23.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 70,300
Avg Vol 187,862
Day's Range N/A - N/A
Shares Out 3.21M
Stochastic %K 37%
Beta -0.84
Analysts Strong Sell
Price Target $39.25

Latest News on CING

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23, 2024, 7:30 AM EST - 25 days ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 7, 2024, 7:30 AM EST - 2 months ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 8, 2024, 3:15 PM EDT - 3 months ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12, 2024, 8:30 AM EDT - 4 months ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Aug 27, 2024, 4:30 PM EDT - 5 months ago

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting

Aug 23, 2024, 4:45 PM EDT - 5 months ago

Cingulate Announces Adjournment of Special Meeting

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 16, 2024, 12:36 PM EDT - 5 months ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15, 2024, 7:45 AM EDT - 5 months ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Aug 13, 2024, 7:45 AM EDT - 5 months ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024, 9:15 AM EDT - 7 months ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 4:30 PM EDT - 7 months ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Jun 25, 2024, 9:20 AM EDT - 7 months ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 8, 2024, 7:00 AM EDT - 9 months ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 30, 2024, 5:45 AM EDT - 9 months ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 16, 2024, 5:00 PM EDT - 9 months ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Apr 1, 2024, 8:00 AM EDT - 10 months ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Attend DCAT Week 2024 in New York City

Mar 6, 2024, 6:45 AM EST - 11 months ago

Cingulate to Attend DCAT Week 2024 in New York City

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 13, 2024, 6:45 AM EST - 1 year ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 6, 2024, 4:15 PM EST - 1 year ago

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 1 year ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 8:00 AM EST - 1 year ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Jan 29, 2024, 6:45 AM EST - 1 year ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 28, 2023, 7:19 AM EST - 1 year ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Dec 1, 2023, 9:00 AM EST - 1 year ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Nov 13, 2023, 4:15 PM EST - 1 year ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Oct 17, 2023, 2:22 PM EDT - 1 year ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 1:30 PM EDT - 1 year ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 1 year ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 13, 2023, 4:15 PM EDT - 1 year ago

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 1 year ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 11, 2023, 6:00 AM EDT - 1 year ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 8, 2023, 4:31 PM EDT - 1 year ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 6, 2023, 9:00 AM EDT - 1 year ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Aug 14, 2023, 4:15 PM EDT - 1 year ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 29, 2023, 8:00 AM EDT - 1 year ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 14, 2023, 3:45 PM EDT - 1 year ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Jun 8, 2023, 7:00 AM EDT - 1 year ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Cingulate to Present at 13th Annual LD Micro Invitational

May 25, 2023, 3:55 PM EDT - 1 year ago

Cingulate to Present at 13th Annual LD Micro Invitational

Cingulate, Indegene to Participate in Benzinga All Live Access Event

May 12, 2023, 3:45 PM EDT - 1 year ago

Cingulate, Indegene to Participate in Benzinga All Live Access Event

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

May 10, 2023, 4:15 PM EDT - 1 year ago

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

May 3, 2023, 6:45 AM EDT - 1 year ago

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

Apr 4, 2023, 6:45 AM EDT - 1 year ago

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

Mar 13, 2023, 6:45 AM EDT - 2 years ago

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

Mar 10, 2023, 4:05 PM EST - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

Cingulate stock skyrockets after ADHD treatment shows positive trial results

Feb 24, 2023, 7:04 AM EST - 2 years ago

Cingulate stock skyrockets after ADHD treatment shows positive trial results

Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD

Feb 23, 2023, 4:30 PM EST - 2 years ago

Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD

Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Jan 4, 2023, 6:45 AM EST - 2 years ago

Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Cingulate Benzinga All Live Access Appearance Rescheduled for December 16

Dec 1, 2022, 2:00 PM EST - 2 years ago

Cingulate Benzinga All Live Access Appearance Rescheduled for December 16

Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

Nov 14, 2022, 6:45 AM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update